Insider · CIK 0001782814
Chris Nolet
Files at JSPR (Jasper Therapeutics, Inc.), AVBP (ArriVent BioPharma, Inc.). First filing -, latest -.
Chris Nolet files SEC Form 4 as director at JSPR (Jasper Therapeutics, Inc.), and also at AVBP (ArriVent BioPharma, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Chris Nolet has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | AVBP ArriVent BioPharma, Inc. | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +13,562 | $0.00 | $0 | 13,562 | Jun 22, 2026 |
| Jul 3, 2025 | JSPR Jasper Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +7,500 | $0.00 | $0 | 7,500 | Jul 3, 2025 |
| Jun 18, 2025 | AVBP ArriVent BioPharma, Inc. | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +15,502 | $0.00 | $0 | 15,502 | Jun 20, 2025 |
Questions about Chris Nolet
Answered from the filings on this page, as of the latest one.
Is Chris Nolet buying or selling?
Chris Nolet has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Chris Nolet's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Chris Nolet has 0.
Where does Chris Nolet file Form 4?
Chris Nolet has filed Form 4 at JSPR (Jasper Therapeutics, Inc.); AVBP (ArriVent BioPharma, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.